ARTICLE | Company News
Amsterdam Molecular neurology, hematology, endocrine/metabolic news
October 31, 2011 7:00 AM UTC
Amsterdam Molecular discontinued development of Glybera after CHMP's second recommendation against approval of the product in the EU for lipoprotein lipase (LPL) deficiency. The company will also re...